· Additional donation of factor therapy fulfils 2014 pledge to donate up to an unprecedented 1 billion IUs for humanitarian use
· More than 75 per cent of people with haemophilia have limited or no access to diagnosis and treatment, especially in the developing world
· More than 17,200 people with haemophilia in over 40 countries have been treated with medicine provided by Sobi and
Sobi™ (STO:SOBI) and
"Through this partnership with
Significant unmet need in developing world
More than 75 per cent of people with haemophilia have limited or no access to diagnosis and treatment, particularly in the developing world. People with severe haemophilia in these countries often do not survive to adulthood; those who do, often face a life of severe disability, isolation and chronic pain. The underlying physical and psychological toll of haemophilia can be significant without reliable access to care.
"Patients are at the center of all that we do, and our support of the WFH Humanitarian Aid Program, together with Sobi, builds on Sanofi Genzyme's legacy of helping patients around the world have access to the treatments they need," said
"For lasting change to become a reality, we need to recognise that access to treatment is a fundamental human right. We are proud to do our part to address this critical health issue, in partnership with
The WFH Humanitarian Aid Program has over the years made significant improvements in providing access to care. A predictable supply of factor therapy is essential to improving treatment and care. In addition, education programs for treaters and patients are critical initiatives helping to develop in-country capacities to improve diagnosis and treatment monitoring; all of which are needed to create a sustainable treatment environment which lead to better outcomes for patients. Sobi and
A far-reaching impact on haemophilia care
With the provision of a consistent supply of factor, corrective surgeries and prophylaxis treatment for young children have become possible. Since initial shipments of Sobi and
· 450 million IUs of clotting factor have treated over 17,200 people in 42 countries
· 900 children under the age of 10 are receiving prophylaxis treatment
· More than 160,000 acute bleeds have been treated
· More than 2,300 surgeries have taken place including those that were life- and limb-saving.
Sobi and
About the WFH Humanitarian Aid Program
The WFH Humanitarian Aid Program improves the lack of access to care and treatment by providing much-needed support for people with inherited bleeding disorders in developing countries. By providing patients with a more predictable and sustainable flow of humanitarian aid donations, the WFH Humanitarian Aid Program makes it possible for patients to receive consistent and reliable access to treatment and care. None of this would be possible without the generous support of Sanofi Genzyme and Sobi, our Founding Visionary Contributors; Bayer, our Visionary Contributor;
About
With more than 100,000 people in 100 countries,
About Sobi™
Sobi is a specialised international biopharmaceutical company transforming the lives of people with rare diseases. Sobi is providing sustainable access to innovative therapies in the areas of haematology, immunology and specialty indications. Today, Sobi employs approximately 1,400 people across
For more information please contact
Sobi
Paula Treutiger, Head of Communication & Investor Relations
+ 46 733 666 599
paula.treutiger@sobi.com
+ 46 708 734 095
linda.holmstrom@sobi.com
Sanofi Media Relations
Tel: +1 (732) 532-5318
Nicolas.Kressmann@sanofi.com
Sanofi Investor Relations
Tel.: +33 (0)1 53 77 45 45
ir@sanofi.com
Postal address SE-112 76
Phone: 46 8 697 20 00 www.sobi.com
https://news.cision.com/swedish-orphan-biovitrum-ab/r/sobi-and-sanofi-donate-up-to-500-million-additional-ius-of-clotting-factor-to-wfh-humanitarian-aid-p,c3134028
https://mb.cision.com/Main/14266/3134028/1263995.pdf
(c) 2020 Cision. All rights reserved., source